4//SEC Filing
Kumar Rakhi 4
Accession 0001140361-24-041789
CIK 0001635088other
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 9:01 PM ET
Size
10.3 KB
Accession
0001140361-24-041789
Insider Transaction Report
Form 4
Kumar Rakhi
Chief Accounting Officer
Transactions
- Tax Payment
Common Shares
2024-09-20$11.97/sh−3,087$36,951→ 209,322 total - Sale
Common Shares
2024-09-23$11.89/sh−250,000$2,972,500→ 209,322 total - Exercise/Conversion
Common Shares
2024-09-23$3.85/sh+250,000$962,500→ 459,322 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-23−250,000→ 500,000 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (250,000 underlying)
Footnotes (3)
- [F1]Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
- [F2]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F3]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Documents
Issuer
Roivant Sciences Ltd.
CIK 0001635088
Entity typeother
Related Parties
1- filerCIK 0001856296
Filing Metadata
- Form type
- 4
- Filed
- Sep 23, 8:00 PM ET
- Accepted
- Sep 24, 9:01 PM ET
- Size
- 10.3 KB